| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-04-29 04:50:59 UTC |
|---|
| Updated at | 2022-04-29 04:50:59 UTC |
|---|
| NP-MRD ID | NP0083968 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | Doxorubicin |
|---|
| Description | Doxorubicin, also known as adriamycin or adriblastina, belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom. Thus, doxorubicin is considered to be an aromatic polyketide lipid molecule. Doxorubicin is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. Doxorubicin exists in all living organisms, ranging from bacteria to humans. Within humans, doxorubicin participates in a number of enzymatic reactions. In particular, doxorubicin can be converted into doxorubicinol deoxaglycone through the action of the enzymes nad(p)H dehydrogenase [quinone] 1, nadph--cytochrome P450 reductase, and xanthine dehydrogenase/oxidase. In addition, doxorubicin can be converted into doxorubicinol; which is mediated by the enzymes carbonyl reductase [nadph] 1, carbonyl reductase [nadph] 3, aldo-keto reductase family 1 member C3, and alcohol dehydrogenase [nadp(+)]. In humans, doxorubicin is involved in doxorubicin metabolism pathway. Doxorubicin is formally rated as a probable carcinogen (by IARC 2A) and is also a potentially toxic compound. Doxorubicin is found in Dracocephalum kotschyi, Ixora coccinea, Streptomyces galilaeus, Streptomyces peucetius, Streptomyces venezuelae and Xylopia laevigata. Doxorubicin was first documented in 1969 (PMID: 5365804). People often experience red discoloration of the urine for a few days (PMID: 1462166) (PMID: 2555273) (PMID: 5772652). |
|---|
| Structure | COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside | ChEBI | | (8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione | ChEBI | | 14-Hydroxydaunomycin | ChEBI | | 14-Hydroxydaunorubicine | ChEBI | | Adriamycin | ChEBI | | Doxorubicine | ChEBI | | Doxorubicinum | ChEBI | | ADR | Kegg | | Adriblastina | Kegg | | (1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside | Generator | | (1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside | Generator | | (8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione | Generator | | (8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione | Generator | | Adriablastin | HMDB | | Adriblastin | HMDB | | Baxter brand OF doxorubicin hydrochloride | HMDB | | Doxorubicin hydrochloride | HMDB | | Doxorubicina ferrer farm | HMDB | | Ferrer brand OF doxorubicin hydrochloride | HMDB | | Onkoworks brand OF doxorubicin hydrochloride | HMDB | | Urokit doxo-cell | HMDB | | Ribosepharm brand OF doxorubicin hydrochloride | HMDB | | Adrimedac | HMDB | | Bedford brand OF doxorubicin hydrochloride | HMDB | | Doxorubicin hexal | HMDB | | Doxorubicin NC | HMDB | | Doxorubicina funk | HMDB | | Doxotec | HMDB | | Kenfarma brand OF doxorubicin hydrochloride | HMDB | | Prasfarma brand OF doxorubicin hydrochloride | HMDB | | Rubex | HMDB | | Tedec meiji brand OF doxorubicin hydrochloride | HMDB | | Cell pharm brand OF doxorubicin hydrochloride | HMDB | | Adriblastine | HMDB | | Columbia brand OF doxorubicin hydrochloride | HMDB | | Doxo cell | HMDB | | Doxo-cell | HMDB | | Elan brand OF doxorubicin hydrochloride | HMDB | | Farmiblastina | HMDB | | Lemery brand OF doxorubicin hydrochloride | HMDB | | Myocet | HMDB | | Onkodox | HMDB | | Ribodoxo | HMDB | | Adriablastine | HMDB | | Bristol-myers squibb brand OF doxorubicin hydrochloride | HMDB | | Doxolem | HMDB | | Doxorubicina tedec | HMDB | | Doxorubicine baxter | HMDB | | Hexal brand OF doxorubicin hydrochloride | HMDB | | Hydrochloride, doxorubicin | HMDB | | Neocorp brand OF doxorubicin hydrochloride | HMDB | | Pfizer brand OF doxorubicin hydrochloride | HMDB | | Urokit doxo cell | HMDB | | Medac brand OF doxorubicin hydrochloride | HMDB |
|
|---|
| Chemical Formula | C27H29NO11 |
|---|
| Average Mass | 543.5193 Da |
|---|
| Monoisotopic Mass | 543.17406 Da |
|---|
| IUPAC Name | (8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione |
|---|
| Traditional Name | doxorubicin |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O |
|---|
| InChI Identifier | InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1 |
|---|
| InChI Key | AOJJSUZBOXZQNB-TZSSRYMLSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Amino acids, peptides, and analogues |
|---|
| Direct Parent | Gamma amino acids and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Gamma amino acid or derivatives
- Amino fatty acid
- Fatty acyl
- Amino acid
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Organopnictogen compound
- Primary amine
- Organooxygen compound
- Organonitrogen compound
- Amine
- Primary aliphatic amine
- Organic oxygen compound
- Carbonyl group
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Aliphatic homomonocyclic compound
|
|---|
| Molecular Framework | Aliphatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|